{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:29Z","timestamp":1792788629365,"version":"4.5.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key Projects of the Hunan Provincial Health Commission","award":["20257546"],"award-info":[{"award-number":["20257546"]}]},{"name":"Chinese Medicine Leading Talents Cultivation Project of the Hunan Provincial Administration of Traditional Chinese Medicine","award":["2022-5"],"award-info":[{"award-number":["2022-5"]}],"id":[{"id":"https:\/\/ror.org\/03x55t826","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Eribulin is used to treat metastatic breast cancer, but its adverse event (AE) profile requires comprehensive analysis using FDA Adverse Event Reporting System (FAERS) data to guide clinical use. We analyzed eribulin-related AE reports in FAERS (Q1 2011 - Q2 2024). Disproportionality analyses (ROR, PRR, MGPS, BCPNN) identified significant AE signals. Our study finalized 3570 AE reports with eribulin as the primary suspect drug from the FAERS database, including 7455 coded AE records. The included patients were predominantly female (90.1%) and aged 35\u201359 years (42.61%). Eribulin-associated AEs spanned 26 organ systems. Only \u201cBlood and lymphatic system disorders\u201d (n\u2009=\u20091,788) met significance across all four algorithms. At the preferred term level, 95 positive disproportionality signals emerged. Common expected AEs included neutropenia, febrile neutropenia, and leukopenia. Critically, serious unexpected AEs not consistently referenced in drug inserts were identified, such as pleural effusion, respiratory failure, and cardiac failure. Clinical use of eribulin requires great attention to blood and lymphatic adverse events, as well as enhanced monitoring and reporting of adverse events not mentioned in the insert to prevent serious AEs.<\/jats:p>","DOI":"10.1371\/journal.pone.0356800","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:25:23Z","timestamp":1789665923000},"page":"e0356800","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of eribulin: A real-world study based on a pharmacovigilance database"],"prefix":"10.1371","volume":"21","author":[{"given":"Yao","family":"Zhou","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital of Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Shen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ling","sequence":"additional","affiliation":[{"name":"Hunan Academy of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiting","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Ge","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4274-4515","authenticated-orcid":true,"given":"Lifang","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"pone.0356800.ref001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"pone.0356800.ref002","first-page":"171","article-title":"Breast Cancer Treatment","volume":"104","author":"KP Trayes","year":"2021","journal-title":"Am Fam Physician"},{"issue":"8","key":"pone.0356800.ref003","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.3390\/md13085016","article-title":"Eribulin in Cancer Treatment","volume":"13","author":"U Swami","year":"2015","journal-title":"Mar Drugs"},{"issue":"8","key":"pone.0356800.ref004","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/156800907783220417","article-title":"How do microtubule-targeted drugs work? An overview","volume":"7","author":"MA Jordan","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"issue":"10","key":"pone.0356800.ref005","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Y Funahashi","year":"2014","journal-title":"Cancer Sci"},{"issue":"5","key":"pone.0356800.ref006","first-page":"2929","article-title":"Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer","volume":"38","author":"W Goto","year":"2018","journal-title":"Anticancer Res"},{"issue":"1","key":"pone.0356800.ref007","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"J Liu","year":"2022","journal-title":"Nat Commun"},{"issue":"9769","key":"pone.0356800.ref008","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"J Cortes","year":"2011","journal-title":"Lancet"},{"key":"pone.0356800.ref009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4137\/BCBCR.S39615","article-title":"Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer","volume":"10","author":"C Twelves","year":"2016","journal-title":"Breast Cancer (Auckl)"},{"issue":"7","key":"pone.0356800.ref010","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.21873\/anticanres.12697","article-title":"Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer","volume":"38","author":"K Sakaguchi","year":"2018","journal-title":"Anticancer Res"},{"issue":"3","key":"pone.0356800.ref011","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s10637-019-00755-x","article-title":"Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial","volume":"37","author":"K Inoue","year":"2019","journal-title":"Invest New Drugs"},{"issue":"3","key":"pone.0356800.ref012","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10549-023-07030-x","article-title":"Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)","volume":"201","author":"K Kobayashi","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"pone.0356800.ref013","first-page":"92558","article-title":"Eribulin in breast cancer: Current insights and therapeutic perspectives","volume":"14","author":"O Oey","year":"2024","journal-title":"World J Exp Med"},{"key":"pone.0356800.ref014","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2165\/11207520-000000000-00000","article-title":"Eribulin","volume":"71","author":"CM Perry","year":"2011","journal-title":"Drugs"},{"key":"pone.0356800.ref015","doi-asserted-by":"crossref","first-page":"113925","DOI":"10.1016\/j.expneurol.2021.113925","article-title":"Clinical and preclinical features of eribulin-related peripheral neuropathy","volume":"348","author":"O Tarasiuk","year":"2022","journal-title":"Exp Neurol"},{"key":"pone.0356800.ref016","doi-asserted-by":"crossref","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS","volume":"13","author":"X Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0356800.ref017","doi-asserted-by":"crossref","first-page":"894685","DOI":"10.3389\/fphar.2022.894685","article-title":"Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS","volume":"13","author":"Z Feng","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0356800.ref018","doi-asserted-by":"crossref","first-page":"1397692","DOI":"10.3389\/fimmu.2024.1397692","article-title":"Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database","volume":"15","author":"M Yu","year":"2024","journal-title":"Front Immunol"},{"issue":"12","key":"pone.0356800.ref019","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-17-1215","article-title":"MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FR\u03b1 Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity","volume":"17","author":"X Cheng","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"pone.0356800.ref020","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/cas.14898","article-title":"Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models","volume":"112","author":"K Furuuchi","year":"2021","journal-title":"Cancer Sci"},{"issue":"14","key":"pone.0356800.ref021","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-\u03b1-Positive Advanced Solid Tumors","volume":"27","author":"T Shimizu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"pone.0356800.ref022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.breast.2021.02.011","article-title":"Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan","volume":"57","author":"Y-J Lin","year":"2021","journal-title":"Breast"},{"issue":"1","key":"pone.0356800.ref023","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.esmoop.2020.100019","article-title":"Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","volume":"6","author":"B Pellegrino","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"pone.0356800.ref024","article-title":"Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study","volume":"28","author":"H-J L\u00fcck","year":"2023","journal-title":"Oncologist"},{"issue":"6","key":"pone.0356800.ref025","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","article-title":"A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer","volume":"23","author":"K Aogi","year":"2012","journal-title":"Ann Oncol"},{"issue":"16","key":"pone.0356800.ref026","doi-asserted-by":"crossref","first-page":"16793","DOI":"10.1002\/cam4.6301","article-title":"Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis","volume":"12","author":"X Gui","year":"2023","journal-title":"Cancer Med"},{"issue":"10","key":"pone.0356800.ref027","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7295","article-title":"Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline\/taxanes","volume":"13","author":"L Chen","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"pone.0356800.ref028","doi-asserted-by":"crossref","first-page":"500","DOI":"10.21873\/invivo.13466","article-title":"Risk Factors for Eribulin-induced Severe Neutropenia in Patients With Recurrent Breast Cancer","volume":"38","author":"S Takada","year":"2024","journal-title":"In Vivo"},{"issue":"4","key":"pone.0356800.ref029","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-008-0755-1","article-title":"Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4","volume":"62","author":"Z-Y Zhang","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"pone.0356800.ref030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00280-012-1976-x","article-title":"Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment","volume":"70","author":"LA Devriese","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"pone.0356800.ref031","article-title":"Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report","volume":"50","author":"X-F Xie","year":"2022","journal-title":"J Int Med Res"},{"issue":"12","key":"pone.0356800.ref032","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","article-title":"Chemotherapy-induced peripheral neurotoxicity","volume":"6","author":"G Cavaletti","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"pone.0356800.ref033","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13058-022-01560-w","article-title":"Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study","volume":"24","author":"N La Verde","year":"2022","journal-title":"Breast Cancer Res"},{"issue":"2","key":"pone.0356800.ref034","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12282-018-0919-8","article-title":"Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study","volume":"26","author":"J Tsurutani","year":"2019","journal-title":"Breast Cancer"},{"issue":"1","key":"pone.0356800.ref035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s13104-017-2882-4","article-title":"Development of interstitial pneumonia during treatment with eribulin: a case report","volume":"10","author":"K Nakamura","year":"2017","journal-title":"BMC Res Notes"},{"key":"pone.0356800.ref036","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2169\/internalmedicine.2779-19","article-title":"Eribulin-induced interstitial pneumonia: a case series and retrospective cohort study","volume":"59","author":"M Murakami","year":"2020","journal-title":"Intern Med"},{"issue":"6","key":"pone.0356800.ref037","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(18)30147-5","article-title":"Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial","volume":"19","author":"S Pernas","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0356800.ref038","first-page":"753","article-title":"Five Cases of Pseudocirrhosis during Eribulin Treatment for Breast Cancer","volume":"51","author":"Y Akaishi","year":"2024","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"pone.0356800.ref039","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s10620-023-08226-3","article-title":"Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature","volume":"69","author":"G Sadlik","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"1","key":"pone.0356800.ref040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13058-019-1202-4","article-title":"Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer","volume":"21","author":"JS Lee","year":"2019","journal-title":"Breast Cancer Res"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:25:29Z","timestamp":1789665929000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356800"}},"subtitle":[],"editor":[{"given":"Jingyu","family":"Wang","sequence":"first","affiliation":[{"name":"Peking University First Hospital","place":["CHINA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0356800","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}